Wockhardt has entered into an agreement with Italy-based Gnosis SpA to market a process-patented product for osteoarthritis.
Wockardt has signed an in-licensing agreement with the Gnosis SpA to market SAMe (S-adenosyl methionine), a pain reliever for patients suffering from Osteoarthritis. The drug also speeds up the formation of cartilage. "SAMMY (SAMe) will complement our pain portfolio and further strengthen our osteoarthritis portfolio. Osteoarthritis is a condition in which low grade inflammation results in pain in the joints, caused by wear and tear of cartilage. Apart from India, the company has manufacturing plants in countries including UK, Ireland and France.